Floatz logo

Silymarin

Non-Alcoholic Fatty Liver Disease

University Hospitals Cleveland Medical CenterPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
73/ 100

Competitive context

139 Active assets in the Non-Alcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Silymarin is also rated in:

colorectal cancerDormant
B
Indicative ·
63 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →
peripheral neuropathyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →